Stay updated with breaking news from Largeb Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 -- Allogene...
Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.
Phase 1b DLBCL-001 study reinforces promising activity and combinability of golcadomide with R-CHOP in patients with previously untreated aggressive B-cell lymphoma Phase 1/2 CC-99282-NHL-001 study...
Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.